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Background & Objectives: Residual cancer burden (RCB) is an impor-
tant marker for patients with breast carcinoma treated with neoadjuvant
chemotherapy (NACT). However, the association is not absolute for re-
sidual disease of hormone receptor-positive luminal type breast carcino-
ma. We analysed which clinicopathological variables including RCB
grade and immunohistochemical (IHC) markers were associated with
survival.
Methods: Expression of annexin-8, galectin-3, bcl-2, calreticulin, clusterin,
ki-67, mucin-1, and p27were assessed in tissuemicroarray slides of 55 post-
NACT resection specimens from luminal type breast carcinoma patients
treated by docetaxel and doxorubicin. Patients’ age (≥45 vs. <45), RCB
grade (RCB-II vs. RCB-III), lymphovascular invasion, and IHC markers
were analysed according to disease-free survival (DFS) using Kaplan-
Meier method and multivariate Cox proportional hazard model.
Results: Ten-year DFS of all patients was 65.7%. Only ki-67 index of
≥5% was associated with shorter DFS by Kaplan-Meier method
(p=0.021). High expression of galectin-3 showed a tendency for shorter
DFS (p=0.1). Patients’ age, (p=0.29), RCB grade (p=0.52),
lymphovascular invasion (p=0.44) and the other IHC markers were not
associated with DFS. Multivariate Cox proportional hazard model
showed that high ki-67 index was the only independent marker for shorter
DFS (hazard ratio, 3.34; 95% confidence interval, 1.26-8.9; p=0.0151).
Conclusion: Ki-67 index in post-NACT resection specimen can be a
surrogate marker for recurrence of luminal type breast carcinoma.
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Background&Objectives: The reported incidence of unsuspected atyp-
ical proliferative lesions (APLs) ranges from 0.06 to 4.6% in reduction
mammoplasty specimens. We aimed to calculate the prevalence of these
lesions at our tertiary breast unit.
Methods:Data pertaining to age, gender, weight, suture orientation, laterality,
clinical indication, number of blocks and outcomes was collected by retriev-
ing and analysing archived histopathology reports from 2013 to 2018.
Results: 490 cases belonging to 488 patients were identified in the 6-year
period (483 females, 5 males). The ages ranged from 16 to 80 years
(median 48 years). A lack of 100% suture coverage was attributed to
the piecemeal nature of some surgical specimens. Of interest, the suture
orientation showed a steep improvement between 2016 and 2017.
There were two main cohorts: BENIGN comprising macromastia,
gynaecomastia and miscellaneous; and POTENTIAL MALIGNANT in-
cluding symmetrisation for contralateral cancer and risk-reducing mas-
tectomy. 15 cases (3.1%) were eventually removed from the final analysis
due to insufficient clinical information.
The most common APL was ALH/ISLN followed by FEA, DCIS, ADH
and invasive carcinoma. The POTENTIAL MALIGNANT cohort
showed a slightly higher incidence of APLs (n=18/475, 3.8%) compared
to the BENIGN cohort (n=13/475, 2.7%).
Conclusion: There has been a steep improvement of suture orientation
signifying an increased surgical recognition of the possibility of margin
re-excision in incidental APLs. Clinical stratification based on a number
of factors such as age, family history, pre-operative imaging and known
genetic riskmay guide appropriate management of such specimens whilst
adopting a pragmatic approach to block-taking.
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Background & Objectives: Ductal breast cancer can be divided into in-
vasive and non-invasive types (cancer in situ – DCIS). Although there is
information about molecular features of these tumours, DCIS remains none
fully described pathology. Thus we need to find novel reliable diagnostic
markers. One could be the сarcinoembryonic antigen related cell adhesion
molecules 1 (CEACAM1). This molecule was described in diverse invasive
types of cancers. The aim our study presented here was to characterise the
exact expression pattern of CEACAM1 in various types of DCIS.
Methods: The investigation was conducted on 20 samples with different
types (papillary, cribriform, solid and comedocarcinoma) and grades (low
and high) of DCIS. The presence of CEACAM1 was detected by the
immunohistochemistry utilizing the mAb С5-1Х/8 (0.1μg/ml).
Results: Low gradeDCIS (papillary and cribriform) was characterised by
apical expression of CEACAM1 on tumour cells which limited the lu-
mens in tumour structures. The disappearance of spaces between cells
(solid DCIS) was accompanied by a vanishing of CEACAM1.
Comedocarcinoma (high-grade DCIS) were characterised by cytoplasmic
and uniform membranous distribution of CEACAM1 with areas of its
absence. Some DCIS cases (cribriform, solid and comedocarcinoma)
were heterogeneous: I. with and without CEACAM1; II. with different
patterns of CEACAM1 expression.
Conclusion:Ductal cancers in situ have different variants of CEACAM1
expression: papillary and cribriform – apical, solid –without CEACAM1,
comedocarcinoma – cytoplasmic and uniform membranous. The growth
of tumour malignancy leads to CEACAM1 distribution translocation and
their disappearance. The presence or lack of CEACAM1 cannot be indi-
cator of malignant intraductal tumours.
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Background & Objectives: Human epidermal growth factor receptor 2
(HER2) overexpression is present in 15-20% of invasive breast cancers,
and is an important predictive and prognostic marker.
Purpose. Determination of HER2 status in patients with invasive breast
cancer (IBC).
Methods: Immunohistochemistry (IHC) was used to study material of 745
patients using Pathway anti-HER2/neu antibody (4B5). Equivocal HER2
(2+) status was specified by SISH hybridization and was performed by the
INFORMHER2 DUAL ISH DNA Probe Cocktail (USA) implementing a
silver tag (HER2 gene, SISH) and a red chromogen (Chr17, Red ISH).
HER2 status by SISH was determined according with ASCO CAP
Guideline 2018 as positive, if HER2/CEP17 ratio ≥2 with HER2≥6,
HER2/CEP17 ratio<2 with HER2≥6. As a positive control for counting
signals were lymphocytes, fibroblasts, endothelial cells.
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